S
Sheri Dubey
Researcher at Merck & Co.
Publications - 63
Citations - 5917
Sheri Dubey is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vaccination & Immunogenicity. The author has an hindex of 31, co-authored 56 publications receiving 5557 citations. Previous affiliations of Sheri Dubey include Johns Hopkins University & United States Military Academy.
Papers
More filters
Journal ArticleDOI
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
John W. Shiver,Tong-Ming Fu,Ling Chen,Danilo R. Casimiro,Mary-Ellen Davies,Robert K. Evans,Zhiqiang Zhang,Adam J. Simon,Wendy L. Trigona,Sheri Dubey,Lingyi Huang,Virginia Harris,Romnie Long,Xiaoping Liang,Larry Handt,William A. Schleif,Lan Zhu,Daniel C. Freed,Natasha Persaud,Liming Guan,Kara Punt,Aimin Tang,Minchun Chen,Keith A. Wilson,Kelly B. Collins,Gwendolyn J. Heidecker,V. Rose Fernandez,Helen C. Perry,Joseph G. Joyce,Karen M. Grimm,James C. Cook,Paul M. Keller,Denise S. Kresock,Henryk Mach,Robert D. Troutman,Lynne Isopi,Donna M. Williams,Zheng Xu,Kathryn E. Bohannon,David B. Volkin,David C. Montefiori,Ayako Miura,Georgia R. Krivulka,Michelle A. Lifton,Marcelo J. Kuroda,Jörn E. Schmitz,Norman L. Letvin,Michael J. Caulfield,Andrew J. Bett,Rima Youil,David C. Kaslow,Emilio A. Emini +51 more
TL;DR: The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine and elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector.
Journal ArticleDOI
Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination
Dan H. Barouch,Sampa Santra,Jörn E. Schmitz,Marcelo J. Kuroda,Tong-Ming Fu,Wendeline Wagner,Miroslawa Bilska,Abie Craiu,Xin Xiao Zheng,Georgia R. Krivulka,Kristin Beaudry,Michelle A. Lifton,Christine E. Nickerson,Wendy L. Trigona,Kara Punt,Dan C. Freed,Liming Guan,Sheri Dubey,Danilo R. Casimiro,Adam J. Simon,Mary-Ellen Davies,Michael Chastain,Terry B. Strom,Rebecca Gelman,David C. Montefiori,Mark G. Lewis,Emilio A. Emini,John W. Shiver,Norman L. Letvin +28 more
TL;DR: The protective efficacy of vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge in rhesus monkeys is reported, with no evidence of clinical disease or mortality after challenge.
Journal ArticleDOI
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
M. Juliana McElrath,M. Juliana McElrath,Stephen C. De Rosa,Stephen C. De Rosa,Zoe Moodie,Sheri Dubey,Lisa Kierstead,Holly Janes,Olivier D. Defawe,Donald K. Carter,John Hural,Rama Akondy,Susan Buchbinder,Michael N. Robertson,Devan V. Mehrotra,Steven G. Self,Steven G. Self,Lawrence Corey,Lawrence Corey,John W. Shiver,Danilo R. Casimiro +20 more
TL;DR: Consistent with previous trials, the MRKAd5 HIV-1 gag/pol/nef vaccine was highly immunogenic for inducing HIV-specific CD8+ T cells and suggest that future candidate vaccines have to elicit responses that either exceed in magnitude or differ in breadth or function from those recorded in this trial.
Journal ArticleDOI
Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
Danilo R. Casimiro,Ling Chen,Tong-Ming Fu,Robert K. Evans,Michael J. Caulfield,Mary-Ellen Davies,Aimin Tang,Minchun Chen,Lingyi Huang,Virginia Harris,Daniel C. Freed,Keith A. Wilson,Sheri Dubey,De-Min Zhu,Denise K. Nawrocki,Henryk Mach,Robert D. Troutman,Lynne Isopi,Donna M. Williams,William M. Hurni,Zheng Xu,Jeffrey G. Smith,Su Wang,Xu Liu,Liming Guan,Romnie Long,Wendy L. Trigona,Gwendolyn J. Heidecker,Helen C. Perry,Natasha Persaud,Timothy J. Toner,Qin Su,Xiaoping Liang,Rima Youil,Michael Chastain,Andrew J. Bett,David B. Volkin,Emilio A. Emini,John W. Shiver +38 more
TL;DR: Results are suggestive of an immunization strategy for humans that is centered on use of the adenovirus vector and in which existing adenavirus immunity may be overcome by combined immunization with adjuvanted DNA and adenvirus vector boosting.
Journal ArticleDOI
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Frances Priddy,Deborah D. Brown,James G. Kublin,Kathleen Monahan,David Wright,Jacob Lalezari,Steven Santiago,Michael Marmor,Michelle Lally,Richard M. Novak,Stephen J. Brown,Priya Kulkarni,Sheri Dubey,Lisa S. Kierstead,Danilo R. Casimiro,Robin Mogg,Mark J. DiNubile,John W. Shiver,Randi Y. Leavitt,Michael N. Robertson,Devan V. Mehrotra,Erin Quirk +21 more
TL;DR: The vaccine was generally well tolerated and induced cell-mediated immune responses against human immunodeficiency virus type 1 peptides in most healthy adults and vaccination in a proof-of-concept trial with use of this vaccine was discontinued because of lack of efficacy.